SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hyliion Holdings Corp. engages in the development of sustainable electricity-producing technology. It focuses on providing modular power plant technology that can operate on various fuel sources through the KARNO power module. The company was founded by Thomas J. Healy in 2015 and is headquartered in Cedar Park, TX.

Hyliion Holdings Corporation - Ordinary Shares - Class A

Hyliion Holdings Corp

Hyliion Holdings is experiencing significant bullish momentum driven by progress in its KARNO power module, including recent military validation and growing interest in its application for AI data center energy needs. The community is actively discussing the stock's pivot from EV trucking to clean energy technology, fueled by optimism over institutional buying, upcoming earnings, and potential commercialization catalysts.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is facing intense volatility as market participants weigh geopolitical tensions in the Middle East against concerns regarding potential quantum computing threats to cryptographic security. The community remains deeply divided, with bulls pointing to supply scarcity and long-term cycle indicators while bears highlight disappointing ETF flows and negative macroeconomic signals.

Harmonic, Inc. engages in the development and sale of video delivery software, products, system solutions, and services. It operates through the Video and Broadband segments. The Video segment sells video processing and production and playout services to cable operators, satellite and telecommunications pay-TV service providers, and broadcast and media companies. The Broadband segment offers solutions to cable operators broadband access solutions and related services, including cOS software-based broadband access solution, to broadband operators globally. The company was founded in June 1988 and is headquartered in San Jose, CA.

Harmonic, Inc.

Harmonic, Inc. is capturing significant market attention as a pure-play broadband software leader, with the community highlighting a structural shift in network infrastructure as a key growth catalyst. Investors are actively debating the sustainability of this transition and its long-term impact on profitability, with sentiment driven by strong backlog numbers and institutional confidence in the firm's pivot away from legacy hardware dependency.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing heightened investor attention as community members debate its potential for a rebound following a successful live-fire demonstration of its LOCUST laser weapon system aboard a U.S. Navy carrier. While bulls are highlighting the stock's role in drone warfare and defense budget tailwinds, others are focused on institutional short-selling pressure and recent price volatility as the market evaluates the company's long-term growth against integration costs.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing heightened social media interest driven by its status as a high-short-interest candidate, with retail traders pointing to an aggressively shrinking float due to active share buybacks and a potential gamma squeeze setup. Community sentiment is overwhelmingly bullish, as participants look toward upcoming earnings and potential institutional shifts to trigger a move past key resistance levels.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is currently a subject of intense debate as traders weigh its limited token supply and potential DeFi role against ongoing concerns over price manipulation and market performance. While some community members remain bullish on its prospects as an undervalued 'sleeping giant,' others are voicing deep frustration, citing recent legal scrutiny and a lack of momentum compared to other DeFi protocols.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Greenwood Village, CO.

Brand Engagement Network Inc

Brand Engagement Network Inc ($BNAI) is trending as investors monitor catalysts surrounding the upcoming Cataneo acquisition and anticipate significant growth from their expansion into the commercial fleet management and pharmaceutical engagement sectors. The community is actively discussing the potential for a major short squeeze due to elevated cost-to-borrow rates, while sentiment remains divided between speculative optimism over enterprise-grade AI deals and concerns over the company's financial reporting and high volatility.

Roundhill ETF Trust - Roundhill Space & Technology ETF

Investors are flocking to MARS as a strategic, actively managed play on the broader space technology sector, frequently comparing its holdings and performance to other space ETFs. The community is actively debating the fund's potential exposure to SpaceX and its concentration in high-growth companies like Rocket Lab and AST SpaceMobile, viewing it as a strong long-term vehicle for gaining diversified access to the burgeoning space economy.

Flowers Foods, Inc. engages in the production and marketing of packaged bakery foods. It offers breads, buns, rolls, snack items, bagels, English muffins, and tortillas and are sold under a variety of brand names, including Nature’s Own, Dave’s Killer Bread, Wonder, Canyon Bakehouse, Tastykake, and Mrs. Freshley’s. The company was founded by William Howard Flowers, Sr. and Joseph Hampton Flowers, Jr. in 1919 and is headquartered in Thomasville, GA.

Flowers Foods, Inc.

Flowers Foods is trending due to a significant strategic expansion through the acquisition of Simple Mills, alongside strong interest in its resilient brand portfolio and high dividend yield despite broader sector pressures. Investors and community members are actively debating the company's ability to navigate current input cost headwinds and potential dividend sustainability as they assess its long-term value.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending as investors await topline data from its Phase 3 Emerge trial for major depressive disorder, while sentiment is split between optimism over its psychiatric pipeline and concerns regarding dilution and historical governance issues. The community is actively debating the company's valuation, upcoming catalyst events, and the potential impact of recent executive orders on the psychedelic sector.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.read more...

RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?

Equity

Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Arvinas (ARVN) delivered earnings and revenue surprises of +5.01% and -0.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu...

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +63.04% and +32.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HC Wainwright Brokers Reduce Earnings Estimates for Arvinas

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Arvinas in a research report issued to clients and investors on Monday, May 4th. HC Wainwright analyst A. Fein now forecasts that the company will ea...

Arvinas (NASDAQ:ARVN) Shares Gap Down - Should You Sell?

Arvinas (NASDAQ:ARVN) Shares Gap Down - Time to Sell...

Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment for ESR1-mutated advanced breast cancer.read more...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

ARVN
Arvinas Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ARVN News

ARVNArvinas Inc